InvestorsHub Logo
icon url

dia76ca

05/23/14 11:13 AM

#177541 RE: spongiformbobsqpants #177540

Tarvacin(TM) Equivalent Plus Radiation Therapy Reduces Tumor Growth by 98%

Monday November 8, 12:09 pm ET
Data Presented at Vascular Targeting Agent Conference in Cambridge, Massachusetts

TUSTIN, Calif., Nov. 8 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM - News) announced today that Philip Thorpe, Ph.D., a member of its scientific advisory board, gave the keynote presentation at the Vascular Targeting Agents conference in Cambridge, Massachusetts. Dr. Thorpe's address highlighted a growing body of pre-clinical evidence supporting the development of Vascular Targeting Agents (VTAs), which are designed to seek and destroy pre-existing blood vessels within cancerous tumors by cutting off the tumor's blood supply.

Also presented was new pre-clinical data generated by Dr. Jin He at UT Southwestern Medical Center at Dallas demonstrating that radiation therapy significantly increases the anti-tumor activity of the Tarvacin(TM) equivalent named 3G4. In animals treated with 3G4 plus external beam radiation, tumor growth was reduced by 98% as compared with 85% for radiation therapy alone or 67% with 3G4 alone.

icon url

asmarterwookie

05/23/14 11:17 AM

#177542 RE: spongiformbobsqpants #177540

spongiformsbobsqpants...Cotara, an Orphan Drug which is Fast Tracked by the FDA is Peregrines drug that is approved for Phase III in Glioblastoma.

Unfortunately there is not a whole lot of money in it so PPHM steered towards Bavituximab.

Bavituximab may have an effect by itself but it is minimal. Time is a factor.

See Cotara for immediate info.

wook
icon url

stockweiser

05/23/14 11:28 AM

#177545 RE: spongiformbobsqpants #177540

As I believe it was CP who stated the brain is the organ of the body that has the most PS one would conclude that Bavi would benefit someone in this area.